查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1741184

基因組癌症檢測市場：按檢測類型、癌症類型、技術、最終用戶、生物標記類型、服務供應商、應用、檢測環境和地區分類

Genomic Cancer Testing Market, By Test Type, By Cancer Type, By Technology, By End-User, By Biomarker Type, By Service Provider, By Application, By Testing Setting, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

基因組癌症檢測市場規模預計在 2025 年達到 220 億美元，預計到 2032 年將達到 648.5 億美元，2025 年至 2032 年的複合年成長率為 16.7%。

報告範圍 報告詳細資訊
基準年 2024 2025年的市場規模 220億美元
效能數據 2020-2024 預測期 2025-2032
預測期：2025-2032年複合年成長率： 16.70% 2032年價值預測 648.5億美元

基因組癌症檢測正在迅速改變腫瘤學領域。透過分析癌細胞的基因組成，這些檢測可以深入了解導致患者患病的突變。這種個人化方法使臨床醫生能夠根據個體的基因譜制定個人化治療方案，並選擇直接針對異常基因的治療藥物。腫瘤基因組分析有助於預測患者對某些藥物的反應，檢測提示高復發風險的基因標記，並識別可以阻斷以阻止癌症生長的生物路徑。隨著基因組技術的不斷進步，癌症檢測正變得越來越全面且經濟實惠。預計未來幾年，這將顯著改善許多癌症患者的預後。

市場動態：

全球基因組癌症檢測市場主要受全球癌症發生率上升和隨之而來的精準醫療需求的驅動。次世代定序(NGS) 技術在生物標記識別的日益廣泛應用也推動了市場成長。然而，缺乏基因組分析所需的基礎設施和熟練的專業人員構成了重大挑戰，尤其是在開發中國家。檢測程序的高成本也進一步限制了它的廣泛應用。然而，私人和公共機構為開發新型診斷工具而提供的資金提供了有利可圖的機會。診斷公司和癌症中心之間的夥伴關係旨在擴大基因組分析的管道。檢測可操作的基因組變異和檢驗伴隨診斷的其他策略措施將進一步刺激基因組癌症檢測市場。此外，預計市場參與企業之間加強合作將在預測期內推動市場成長。例如，2023年4月，人工智慧和精準醫療領域的領導者Tempus宣布與禮來公司（Eli Lilly and Company）達成一項新的合作，旨在擴大合格的進行性或轉移性甲狀腺髓樣癌（MTC）以及進行性或轉移性非髓樣甲狀腺癌（non-MTC）患者的基因組檢測覆蓋範圍。此次合作將免費提供Tempus的分子分析服務，同時與醫師合作，透過更廣泛的基因組檢測，為病患提供數據驅動的醫療服務。

本研究的主要特點

  • 本報告對全球基因組癌症檢測市場進行了詳細分析，並提供了 2025 年至 2032 年期間的市場規模和預測年複合成長率（CAGR%），以 2024 年為基準年。
  • 它還強調了各個領域的潛在商機，並說明了該市場的有吸引力的投資提案矩陣。
  • 它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
  • 全球基因組癌症檢測市場的主要企業是根據公司亮點、產品系列、關鍵亮點、財務績效和策略等參數進行的分析。
  • 本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、新興車型、市場擴張和行銷策略做出明智的決策。
  • 全球基因組癌症檢測市場報告針對該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
  • 可以透過用於分析全球基因組癌症檢測市場的各種策略矩陣來促進相關人員的決策。

目錄

第1章 調查目的與前提條件

  • 研究目標
  • 先決條件
  • 簡稱

第2章 市場展望

  • 報告描述
    • 市場定義和範圍
  • 執行摘要
  • Coherent Opportunity Map（COM）

第3章市場動態、法規與趨勢分析

  • 市場動態
    • 癌症發生率增加
    • 高成本
    • 癌症發生率增加
  • 影響分析
  • 主要亮點
  • 監管情景
  • 產品發布/核准
  • PEST分析
  • 波特分析
  • 併購場景

4. 全球基因組癌症檢測市場-冠狀病毒（COVID-19）大流行的影響

  • COVID-19流行病學
  • 供需側分析
  • 經濟影響

5. 全球基因組癌症檢測市場（依檢測類型），2020 年至 2032 年

  • 基因組分析測試
  • 液態生物檢體
  • 伴隨診斷測試
  • 藥物基因組學檢測
  • 遺傳性癌症檢測
  • 其他專門的基因組測試

6. 全球基因組癌症檢測市場（以癌症類型），2020 年至 2032 年

  • 乳癌
  • 肺癌
  • 大腸直腸癌
  • 攝護腺癌
  • 卵巢癌
  • 黑色素瘤
  • 白血病
  • 淋巴瘤
  • 其他特定癌症類型

7. 全球基因組癌症檢測市場（依技術分類），2020 年至 2032 年

  • 次世代定序（NGS）
  • 聚合酵素鏈鎖反應（PCR）
  • 螢光原位雜合反應（FISH）
  • 微陣列
  • 免疫組織化學（IHC）
  • 其他基因組檢測技術

8. 全球基因組癌症檢測市場（依最終用戶分類），2020 年至 2032 年

  • 醫院
  • 診斷實驗室
  • 學術研究所
  • 癌症中心
  • 其他醫療保健提供者

9. 全球基因組癌症檢測市場（依生物標記類型），2020 年至 2032 年

  • 基因生物標記
  • 蛋白質生物標記
  • 分子生物標記
  • 表觀遺傳生物標記

10. 全球基因組癌症檢測市場（按服務供應商分類），2020 年至 2032 年

  • 診斷實驗室
  • 生技公司
  • 製藥公司
  • 合約研究組織（CRO）

第 11 章。 2020 年至 2032 年按地區分類的全球基因組癌症檢測市場

  • 北美洲
      • 美國
      • 加拿大
  • 拉丁美洲
      • 巴西
      • 墨西哥
      • 阿根廷
      • 其他拉丁美洲
  • 歐洲
      • 英國
      • 德國
      • 義大利
      • 法國
      • 西班牙
      • 俄羅斯
      • 其他歐洲國家
  • 亞太地區
      • 中國
      • 印度
      • 日本
      • ASEAN
      • 澳洲
      • 韓國
      • 其他亞太地區
  • 中東
      • GCC
      • 以色列
      • 其他中東地區
  • 非洲
      • 北非
      • 中部非洲
      • 南非

第12章競爭格局

  • Illumina, Inc.
  • Thermo Fisher Scientific, Inc.
  • Qiagen NV
  • F.Hoffmann-La Roche Ltd.
  • Foundation Medicine, Inc.（Roche）
  • Invitae Corporation
  • NeoGenomics Laboratories, Inc.
  • Myriad Genetics, Inc.
  • Genomic Health, Inc.（Exact Sciences Corporation）
  • Caris Life Sciences
  • ArcherDX, Inc.（Invitae Corporation）
  • Guardant Health, Inc.
  • Personal Genome Diagnostics Inc.
  • Biocept, Inc.
  • Tempus Labs, Inc.

第13章 章節

  • 調查方法
  • 關於出版商
簡介目錄
Product Code: CMI5914

Genomic Cancer Testing Market is estimated to be valued at USD 22.00 Bn in 2025 and is expected to reach USD 64.85 Bn by 2032, growing at a compound annual growth rate (CAGR) of 16.7% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 22.00 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 16.70% 2032 Value Projection: USD 64.85 Bn

Genomic cancer testing is rapidly transforming the field of oncology. It involves analyzing the genetic makeup of cancer cells to gain insights into the mutations driving a patient's disease. This personalized approach enables clinicians to tailor treatment based on an individual's genetic profile and select therapeutics that directly target the abnormalities present. The genomic analysis of a tumor helps predict response to certain drugs, checks for genetic markers that may indicate higher risk of recurrence, and pinpoints biological pathways that can be blocked to stop cancer growth. With continued advances in genomic technologies, cancer testing is becoming more comprehensive and affordable. This is expected to significantly improve outcomes for many cancer patients in the coming years.

Market Dynamics:

The global genomic cancer testing market is primarily driven by rising cancer burden worldwide and subsequent demand for precision medicine approaches. Growing application of next-generation sequencing (NGS) technologies for biomarker identification is also fueling market growth. However, lack of infrastructure and skilled professionals required for genomic analysis poses a major challenge, especially in developing nations. High cost of testing procedures further limits widespread adoption. Yet funding from private and public bodies to develop novel diagnostic tools presents lucrative opportunities. Partnerships between diagnostic companies and cancer centers aim to expand access to genomic profiling. Other strategic initiatives to detect actionable genomic alterations and validate companion diagnostics will further stimulate the genomic cancer testing market. MOrevoer, increasing collaboration between market players is expected to drive the market growth over forecast period. For instance, in April 2023, Tempus, a leader in artificial intelligence and precision medicine, today announced a new collaboration sponsored by Eli Lilly and Company designed to expand access to genomic testing for eligible patients who have advanced or metastatic medullary thyroid cancer (MTC) OR advanced or metastatic non-medullary thyroid cancer (non-MTC). This collaboration offers Tempus' molecular profiling offerings at no cost while simultaneously working with physicians to support them in providing data-driven treatment to their patients with the use of broad-panel genomic testing.

Key features of the study:

  • This report provides in-depth analysis of the global genomic cancer testing market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global genomic cancer testing market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Illumina, Inc., Thermo Fisher Scientific, Inc., Qiagen N.V., F. Hoffmann-La Roche Ltd., Foundation Medicine, Inc. (Roche), Invitae Corporation, NeoGenomics Laboratories, Inc., Myriad Genetics, Inc., Genomic Health, Inc. (Exact Sciences Corporation), Caris Life Sciences, ArcherDX, Inc. (Invitae Corporation), Guardant Health, Inc., Personal Genome Diagnostics Inc., Biocept, Inc., and Tempus Labs, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global genomic cancer testing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global genomic cancer testing market

Detailed Segmentation:

  • Global Genomic Cancer Testing Market, By Test Type:
    • Genomic Profiling Tests
    • Liquid Biopsy Tests
    • Companion Diagnostic Tests
    • Pharmacogenomic Tests
    • Hereditary Cancer Tests
    • Other specialized genomic tests
  • Global Genomic Cancer Testing Market, By Cancer Type:
    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Ovarian Cancer
    • Melanoma
    • Leukemia
    • Lymphoma
    • Other specific cancer types
  • Global Genomic Cancer Testing Market, By Technology:
    • Next-Generation Sequencing (NGS)
    • Polymerase Chain Reaction (PCR)
    • Fluorescence In Situ Hybridization (FISH)
    • Microarray
    • Immunohistochemistry (IHC)
    • Other genomic testing technologies
  • Global Genomic Cancer Testing Market, By End User:
    • Hospitals
    • Diagnostic Laboratories
    • Academic and Research Institutions
    • Cancer Centers
    • Other healthcare providers
  • Global Genomic Cancer Testing Market, By Biomarker Type:
    • Genetic Biomarkers
    • Protein Biomarkers
    • Molecular Biomarkers
    • Epigenetic Biomarkers
  • Global Genomic Cancer Testing Market, By Service Provider:
    • Diagnostic Laboratories
    • Biotechnology Companies
    • Pharmaceutical Companies
    • Contract Research Organizations (CROs)
  • Global Genomic Cancer Testing Market, By Application:
    • Targeted Therapy Selection
    • Disease Monitoring
    • Prognostic Testing
    • Companion Diagnostics
    • Risk Assessment
    • Pharmacogenomic Testing
  • Global Genomic Cancer Testing Market, By Testing Setting:
    • In-House Testing
    • Outsourced Testing
  • Global Genomic Cancer Testing Market, By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East and Africa
  • Company Profiles:
    • Illumina, Inc.
    • Thermo Fisher Scientific, Inc.
    • Qiagen N.V.
    • F. Hoffmann-La Roche Ltd.
    • Foundation Medicine, Inc. (Roche)
    • Invitae Corporation
    • NeoGenomics Laboratories, Inc.
    • Myriad Genetics, Inc.
    • Genomic Health, Inc. (Exact Sciences Corporation)
    • Caris Life Sciences
    • ArcherDX, Inc. (Invitae Corporation)
    • Guardant Health, Inc.
    • Personal Genome Diagnostics Inc.
    • Biocept, Inc.
    • Tempus Labs, Inc.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Genomic Cancer Testing, By Test Type
    • Market Genomic Cancer Testing, By Cancer Type
    • Market Genomic Cancer Testing, By Technology
    • Market Genomic Cancer Testing, By End User
    • Market Genomic Cancer Testing, By Biomarker Type
    • Market Genomic Cancer Testing, By Service Provider
    • Market Genomic Cancer Testing, By Application
    • Market Genomic Cancer Testing, By Testing Setting
    • Market Genomic Cancer Testing, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Increasing Cancer Incidence
    • High Costs
    • Increasing Cancer Incidence
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Genomic Cancer Testing Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Genomic Cancer Testing Market, By Test Type, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Genomic Profiling Tests
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Liquid Biopsy Tests
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Companion Diagnostic Tests
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Pharmacogenomic Tests
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Hereditary Cancer Tests
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Other specialized genomic tests
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Global Genomic Cancer Testing Market, By Cancer Type, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Breast Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Lung Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Colorectal Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Prostate Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Ovarian Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Melanoma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Leukemia
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Lymphoma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Other specific cancer types
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

7. Global Genomic Cancer Testing Market, By Technology, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Next-Generation Sequencing (NGS)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Polymerase Chain Reaction (PCR)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Fluorescence In Situ Hybridization (FISH)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Microarray
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Immunohistochemistry (IHC)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Other genomic testing technologies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

8. Global Genomic Cancer Testing Market, By End User, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Diagnostic Laboratories
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Academic and Research Institutions
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Cancer Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Other healthcare providers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

9. Global Genomic Cancer Testing Market, By Biomarker Type, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Genetic Biomarkers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Protein Biomarkers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Molecular Biomarkers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Epigenetic Biomarkers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

10. Global Genomic Cancer Testing Market, By Service Provider, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021- 2032
    • Segment Trends
  • Diagnostic Laboratories
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Biotechnology Companies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Pharmaceutical Companies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Contract Research Organizations (CROs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

11. Global Genomic Cancer Testing Market, By Region, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, By Region, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, For Region, 2021-2032
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Service Provider, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Testing Setting, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Service Provider, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Testing Setting, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Service Provider, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Testing Setting, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Service Provider, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Testing Setting, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Service Provider, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Testing Setting, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country , 2020-2032,(US$ Bn)
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Service Provider, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Testing Setting, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region , 2020-2032,(US$ Bn)
      • North Africa
      • Central Africa
      • South Africa

12. Competitive Landscape

  • Illumina, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Thermo Fisher Scientific, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Qiagen N.V.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • F.Hoffmann-La Roche Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Foundation Medicine, Inc. (Roche)
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Invitae Corporation
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • NeoGenomics Laboratories, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Myriad Genetics, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Genomic Health, Inc. (Exact Sciences Corporation)
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Caris Life Sciences
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • ArcherDX, Inc. (Invitae Corporation)
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Guardant Health, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Personal Genome Diagnostics Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Biocept, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Tempus Labs, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Analyst Views
  • Analyst Views

13. Section

  • Research Methodology
  • About us